Traditional Chinese medicine industry shuffles into an irreversible trend, and traditional enterprises transform into Biopharmaceutics

[trends of pharmaceutical network industry] in recent years, with the strengthening of a series of management and control, the shuffling of traditional Chinese medicine industry has become an irreversible trend The industry believes that due to the special properties of traditional Chinese medicine, it will become a certain trend for traditional Chinese medicine enterprises to transform the pipeline reserve of biological medicine research and development In fact, in the field of traditional Chinese medicine, there are many examples of transformation from traditional pharmaceutical enterprises to biopharmaceutics For example, listed pharmaceutical enterprises such as Jiuzhitang, Tianshili, Yunnan Baiyao and Changbu pharmaceutical are all laying out the field of biopharmaceutics What are the achievements of these pharmaceutical enterprises after the transformation? Jiuzhitang has been seeking transformation through investment in biological medicine and layout of daily chemical industry since Youbo pharmaceutical entered in 2015 However, due to the inability of Jiuzhitang to focus on a transformation market, there will be greater uncertainty in its performance The semi annual report of Jiuzhitang in 2019 shows that in the first half of 2019, the operating revenue reached 1.689 billion yuan, a year-on-year decrease of 6.23%; the net profit attributable to shareholders of the listed company was 176 million yuan, a year-on-year decrease of 46%; the net profit attributable to shareholders of the listed company after deducting non recurring profit and loss was 154 million yuan, a year-on-year decrease of 46.04% In addition, according to the information of the company's third quarter report, Jiuzhitang achieved revenue and net profit of 2.548 billion yuan and 334 million yuan in the first three quarters, down 7.38% and 35.08% year on year respectively At present, Tianshili biology, a traditional Chinese medicine enterprise, has been transformed into a rare full industrial chain commercial platform integrating R & D, production and sales With its R & D advantages in three major treatment fields, namely, cardio cerebrovascular, tumor, immune, digestive and metabolism, it has rapidly promoted the research pipeline with international competitive advantages According to the semi annual report, in the first half of 2019, tisli achieved a revenue of 9.417 billion yuan, an increase of 11.10% year-on-year; a net profit of 2.548 billion yuan, a decrease of 2.73% year-on-year; and a deduction of 2.205 billion yuan, an increase of 43.10% year-on-year In addition, in the first half of 2019, the net profit attributable to the parent company was 899 million yuan, down 2.86% year-on-year; the net profit attributable to the parent company after deducting non profits was 836 million yuan, up 0.44% year-on-year Yunnan Baiyao as early as September 2018, Yunnan Baiyao announced that the company will transform from a localized enterprise to a global enterprise, make full use of the company's advantages in natural medicine, plant medicine and traditional Chinese medicine, realize the cross-border development of the pharmaceutical industry, make full efforts to build the biopharmaceutical industry chain, and enhance the R & D strength of biopharmaceuticals According to the announcement issued by Yunnan Baiyao in the first half of 2019, the group achieved a total operating revenue of 13.897 billion yuan in the first half of this year, a net increase of 752 million yuan and a growth rate of 5.72% compared with 13.145 billion yuan in the same period of last year The company said that in the future, it will continue to be based on its main business, stabilize the stock market, adjust its structure, accelerate its transformation and innovation, create increment and enhance its core competitiveness At the same time, it will further strengthen the cost control ability, reduce production costs, actively focus on M & A opportunities, continuously expand business boundaries, enrich product reserves, increase the promotion of new products, and maintain the stability of business performance Step pharmaceutical is now transforming from Chinese patent medicine to biological medicine, chemical medicine, medical equipment and Internet medicine On August 28, step pharmaceutical disclosed the semi annual report of 2019, which showed that in the first half of 2019, the company's operating revenue was 6.405 billion yuan, an increase of 11.43% year on year, and the net profit attributable to shareholders of listed companies was 799 million yuan, an increase of 13.96% year on year According to the company, in combination with the development characteristics of the industry, the company is now based on traditional Chinese patent medicine and is transforming its layout to biological medicine research and development.